Board of Directors
Beverly A. Huss
Ms. Huss joined our Board of Directors in January 2018. Since 2013, she has served as President and Chief Executive Officer of Qool Therapeutics, Inc., formerly Thermocure, Inc., a development stage company focused on creating a novel non-invasive device for the preservation of tissue following a heart attack, stroke, traumatic brain injury and other medical conditions. Prior to joining Qool, Ms. Huss was President and Chief Executive Officer at start-up medical device company Vibrynt, Inc., and held multiple senior level leadership positions at Guidant Corporation, including, most recently President, Endovascular Solutions, and Vice President, Global Marketing, Vascular Intervention and Vice President of the Stent Business Unit.
Ms. Huss also currently serves on the boards of Qool Therapeutics, Inc., Surefire Medical, Inc., and Madorra. Her prior public company board experience includes Artes Medical, Wright Medical Group, and Dade Behring, Inc.
Ms. Huss holds an M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois.
Class II Director, Term Expires 2020Independent Director
Elizabeth Dávila has served as a member of our Board of Directors since February 2008 and as Vice Chairperson of our Board of Directors since September 2008. Ms. Dávila was the former Chairman and Chief Executive Officer of VISX, Incorporated, or VISX, a manufacturer of laser vision correction systems, which was acquired by Advanced Medical Optics in May 2005. Prior to becoming Chairman and Chief Executive Officer of VISX in 2001, she served as President and Chief Operating Officer of VISX from 1999 to 2001 and as Executive Vice President and Chief Operating Officer from 1995 to 1999. Ms. Dávila currently serves as a member of the board of directors of NuGEN Technologies, Inc. and Afaxys, Inc. Ms. Dávila previously served on the boards of directors of Advanced Medical Optics, Inc. (now Abbott Medical Optics), Cholestech Corp. and VidaMed, Inc., medical device companies which were acquired in 2009, 2007 and 2002, respectively. Ms. Dávila holds a B.S. in Chemistry from St. Mary’s College, an M.S. in Chemistry from the University of Notre Dame and an M.B.A. from Stanford University.
Class III Director, Term Expires 2018Independent Director
Jack Goldstein PhD
Jack Goldstein, Ph.D., has served as a member of our Board of Directors since May 2010. Dr. Goldstein is currently an independent consultant. He served as President and Chief Operating Officer of Chiron Corporation from 2004 until its acquisition by Novartis in 2006, and from 2002 to 2004 he served as President of Chiron’s Blood Testing Division. From 2000 to 2002, he was a general partner at Windamere Venture Partners. From 1997 to 2001, he served as President and Chief Executive Officer at Applied Imaging Corporation, and from 1999 until 2002, he also served as Chairman of the Board of Applied Imaging. From 1986 to 1997, Dr. Goldstein served in various executive positions at Johnson & Johnson, including President of Ortho Diagnostic Systems and Executive Vice President of Professional Diagnostics. Dr. Goldstein previously served as Chairman of the Board of Directors of OncoGenex Pharmaceuticals, Inc., from March 2010 to August 2017. Dr. Goldstein holds a Bachelor of Arts degree in biology from Rider University and a Master of Science degree in immunology and a Ph.D. in microbiology from St. John’s University.
Class II Director, Term Expires 2020Independent Director
Louis J. Lavigne, Jr.
After 23 years with Genentech, Inc., Lavigne is now a management consultant specializing in the areas of corporate finance, accounting and strategy. He retired as Executive Vice President and Chief Financial Officer of Genentech in March, 2005. He joined Genentech in July,1982 and was named Controller in 1983 and built Genentech’s operating financial functions. In 1986, he was promoted to Vice President and assumed the CFO position in September 1988. He became Senior Vice President in July,1994 and Executive Vice President in March,1997. Lavigne was a member of Genentech’s Executive Committee and chairman of its 401K Plan Committee. Genentech's revenues grew significantly during Lavigne’s tenure: from $40 million when he became Controller in 1983, to ~ $300 million when he became CFO in 1988 and were over $6.6 billion in 2005.
Lavigne was responsible for Genentech’s Financial, Corporate Relations, and Information Technology groups and was named the Best CFO in Biotech in 2005 in the Institutional Investor survey. In June, 2006, he received the Bay Area CFO of the Year-Hall of Fame-Lifetime Achievement Award.
Prior to joining Genentech, Lavigne held various financial management roles with Pennwalt Corporation, a chemical and pharmaceutical company.
He is a member of the Board of Directors of Accuray Incorporated (and Chairman of the Board & Compensation Committee), Zynga, Inc., Depomed, Inc., DocuSign Inc., Novocure Limited, Puppet, Inc. and Rodan & Fields. Previously he was a Director and Chairman of the Audit Committee of several other public companies: Allergan, Inc., Arena Pharmaceuticals, BCM Software, Equinix, Kyphon, SafeNet, Inc. and Xenova, PLC. He is also member of the Pacific SW Audit Committee Network of Audit Committee Chairs.
He is a member of the Board and former Chairman of UCSF Benioff Children's Hospitals and their foundation.
Lavigne earned a bachelor’s degree in business administration from Babson College in 1969 and an M.B.A. from Temple University in 1976.
Class II Director, Term Expires 2020Independent DirectorChairman of the Board
Joshua H. Levine
Joshua H. Levine joined Accuray in October 2012 as President and Chief Executive Officer, and Director of the Board. Levine brings extensive experience from a career spanning three decades in the medical device/medical technology industry, having worked in a variety of market leading organizations including American Hospital Supply, Kinetic Concepts (KCI), Mentor, Johnson & Johnson, and Immucor.
Levine served as President and CEO of Mentor Corporation from 2004 through early 2009 and led the company through a strategic transformation prior to its sale to Johnson & Johnson. Levine spent a total of 15 years at Mentor, where he held various Sales, Marketing and Management roles including Chief Operating Officer and Senior Vice President of Global Sales and Marketing. Most recently, he served as President and CEO of Immucor Corporation. Levine holds a Bachelor of Arts degree in Communications from the University of Arizona and has completed Executive Management Programs at Stanford University, Graduate School of Business and the University of Pennsylvania, Wharton School.
Class III Director, Term Expires 2018
Richard R. Pettingill
Richard R. Pettingill has served as a member of our Board of Directors since May, 2012. Mr. Pettingill served as the President and Chief Executive Officer of Allina Hospitals and Clinics, Minnesota’s largest healthcare organization, from 2002 until his retirement in 2009. While in this role, he also served on the board of directors of the Minnesota Hospital Association and the Minnesota Business Partnership. Prior to joining Allina Hospitals and Clinics, Mr. Pettingill served as President and Chief Executive Officer of the California Division of Kaiser Foundation Health Plans and Hospitals, one of the largest not-for-profit managed healthcare companies in the United States, from 1996 to 2002. Mr. Pettingill currently serves on the board of directors of Hanger, Inc., an orthotic and prosthetic solutions company. Mr. Pettingill received a bachelor’s degree from San Diego State University and a master’s degree in health care administration from San Jose State University. He served as a 2010 Fellow in the Advanced Leadership Initiative program at Harvard University.
Class I Director, Term Expires 2019Independent Director
Robert S. Weiss
Robert S. Weiss has served as a member of our Board of Directors since January 2007. Since May 2018, Mr. Weiss has served as an advisor to The Cooper Companies, Inc., or Cooper, a global specialty medical products company. He also served as Chief Executive Officer and President of Cooper from November 2007 through April 2018 and March 2008 through April 2018, respectively. Mr. Weiss has served in various senior executive management positions with Cooper since 1989. From January 2005 through October 2007, Mr. Weiss served as the Executive Vice President and Chief Operating Officer of Cooper, and from March 2007 to March 2008, he also served as President of CooperVision, Cooper’s contact lens subsidiary. Prior to that, he served as Cooper’s Chief Financial Officer from September 1989 to January 2005 and held the title of Executive Vice President from October 1995 onward. From March 1984 until October 1995 he served at Cooper in various other roles, including Senior Vice President, Vice President and Corporate Controller. Mr. Weiss also serves on the board of directors of Cooper. Mr. Weiss holds a B.S. in Accounting from the University of Scranton.
Class I Director, Term Expires 2019Financial ExpertIndependent Director